BackgroundAlthough psychedelics have regained attention as potential treatment tools for various mental disorders, little research has examined their impact on temporal perception.AimsThis double-blinded placebo-controlled study aimed to investigate changes in temporal perception under psilocybin, both through performance during the Temporal Bisection Task (...
Unknown journal
2025-12-31
Scholle P, Wenke Š, Nekovářová T, Zaytseva Y, Tylš F, Brunovský M, Horáček J, Andrashko V, Koudelka V, Viktorinová M, Viktorin V, Hájková K, Kuchař M, Páleníček T.
Europe PMC Published
psilocybin ConsciousnessClinical TrialHealthy Volunteers Clinical Trial
Psilocybin, a tryptamine-derived alkaloid from Psilocybe mushrooms, has emerged as a high-value biopharmaceutical candidate due to its promising applications in mental health. While clinical studies highlight its rapid and sustained antidepressant effects, current challenges lie in achieving scalable, reproducible, and cost-effective production to meet growi...
Unknown journal
2025-12-30
Islas-Vargas J, Armenta S, Rivera-Román ÁA, Hernández-León S, Méndez-Hernández JE, Arce-Cervantes O.
Europe PMC Published
psilocybin Mechanism of Action Other HumansEscherichia coli
BackgroundExisting tools assess psychedelic experiences, but none specifically measure altered processing of traumatic memories-a key mechanism in trauma-focused therapies and psychotherapy in general. The helioscope effect describes how psychedelics like psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) enable revisiting challenging or traumatic exper...
Unknown journal
2025-12-30
Diehl VJ, Calder AE, Hasler G.
Europe PMC Published
psilocybin Mechanism of ActionMystical ExperienceObservational Study Observational Study
Distinguishing metabolite isomers often relies on comparing relative data, such as relative chromatographic retention times and ion mobility arrival time orders, or relative product ion abundances. These approaches necessitate the need for quality reference data and/or chemical standards. An ideal method for differentiating isomers would leverage one of the ...
Unknown journal
2025-12-29
Christopher MW, Prentice BM, Garrett TJ.
Europe PMC Published
psilocybinpsilocin General Other DeuteriumDeuterium Exchange Measurement
Psilocybin, an indole alkaloid of psychedelic mushrooms, has the potential to sustainably improve the treatment of several psychiatric diseases. So far, the psilocybin demand for clinical trials has been met by chemical synthesis. In this study, we pursued the biotechnological approach to develop a psilocybin production process utilizing an overproduction st...
Unknown journal
2025-12-29
Weiser S, Jung S, Bardl B, Kufs JE, Janevska S, Valiante V, Hoffmeister D, Regestein L.
Europe PMC Published
psilocybin Clinical Trial Clinical Trial Aspergillus nidulansOxygen
Background: Psilocybin has shown promise in neuropsychiatric disorders but presents a paradoxical relationship with seizures and epilepsy. Methods:: A narrative review was conducted up to November 23, 2025. We conducted structured literature searches across PubMed/MEDLINE, Scopus, Web of Science. and Google Scholar using MeSH terms and keywords to identify s...
Authorea Preprints
2025-12-28
Cervera-Sanchez MB, San-Juan D, Díaz-Peregrino R, Camacho-Castillo EZ, Bringas-Ortiz SA, Padilla-Cabezutd C.
Europe PMC PREPRINT (not peer reviewed)
psilocybinpsilocin Receptor PharmacologyClinical TrialReview ArticleObservational StudyAnimal StudySafety Clinical Trial
Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing numbers of randomized controlled trials (RCTs) and meta-analyses, a comprehensive synthesis of the evidence across different substances and indications is lacking. This umbrella review aims to evaluate the effectiven...
Unknown journal
2025-12-28
Dominiak M, Gędek A, Modrzejewski S, Permoda-Pachuta A, Antosik AZ.
Europe PMC Published
psilocybin DepressionPTSDAddictionRandomized Controlled TrialReview ArticleSafetyAdverse Events Randomized Controlled Trial
The therapeutic potential of low, non-psychedelic doses of psilocybin, a fungal tryptamine alkaloid, was investigated in metabolic disorders including obesity, type 2 diabetes mellitus (T2DM), and liver steatosis. Mice fed a high-fat/high-fructose diet received chronic treatment with psilocybin (0.05 mg/kg) for 12 weeks. Body weight, liver histology, insulin...
Unknown journal
2025-12-28
Colognesi M, Gabbia D, Signor A, Sarill M, Centofanti L, Rinaldi A, Cascione L, Nunziata S, Banzato M, Mattarei A, Finzi G, Sonda S, Pendin D, Zanotto I, Comai S, Pasut G, Alajati A, Saponaro M, Bucciarelli L, Lunati ME, Guarato G, Goggi I, La Rosa S, Morano C, Paroni RC, Dei Cas M, Daniele G, Gentilucci M, Pappagallo M, Alimonti A, Manfredi PL, Folli F, De Martin S.
Europe PMC Published
psilocybin PharmacologyMechanism of ActionReceptor PharmacologyAnimal StudyTranscriptomics Animal Study LiverAnimals
Psychedelic use has greatly increased within clinical and recreational settings over recent years. While demonstrating a favorable safety profile within certain clinical populations, little empirical research has explored safety of psychedelic use within real-world samples. Using the World Health Organization (WHO) VigiBase, a comprehensive global pharmacovi...
Unknown journal
2025-12-28
Syed OA, Nestor SM, Husain MI, Sinyor M, Alam F, Giacobbe P.
Europe PMC Published
psilocybin AddictionAdolescentsSafetyAdverse Events Other HumansSubstance-Related Disorders
ObjectiveThe goals of this study were to examine the therapeutic effects and safety of psilocybin given as a pulsed regimen for the prevention of migraine and to consider the blinding integrity of an active control agent.BackgroundThe administration of a single low dose of psilocybin was observed to have lasting therapeutic effects in one small pilot trial i...
Unknown journal
2025-12-28
Schindler EAD, Gottschalk CH, Pittman BP, D'Souza DC.
Europe PMC Published
psilocybin Headache / MigraineClinical TrialRandomized Controlled TrialSafetyAdverse Events Randomized Controlled Trial HumansHallucinogens
Psychedelic compounds significantly reshape conscious perception, yet the implications of these alterations for complex visual-guided behaviors remain poorly understood. We investigated how psilocybin modulates visual salience processing during natural scene perception. Twenty-three participants completed eye-tracking tasks under self-blinded low and high do...
Unknown journal
2025-12-25
Muller S, Cavanna F, de la Fuente LA, Bruno N, D'Amelio TA, Pallavicini C, Tagliazucchi E.
Europe PMC Published
psilocybin General Other
Psychedelics such as psilocybin, LSD, and MDMA have shown promise in treating mental health conditions (e.g., depression, post-traumatic stress disorder) among neurotypical individuals, i.e., typically developing individuals without a diagnosed neurodevelopmental condition. However, their therapeutic potential for treating co-occurring mental-health conditio...
Unknown journal
2025-12-25
Afsharnia S, Liang V, Lunsky Y, Orsini AP, Tint A, Lin HY.
Europe PMC Published
psilocybin DepressionPTSDClinical TrialObservational StudySafety Clinical Trial
BackgroundThe Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psychedelic research. However, its original dimensional model (3D-ASC within 5D-ASC) and later 11-subscale structure (11-ASC) have a hierarchically incompatible higher/lower-order structure. Although the 11-...
Unknown journal
2025-12-25
Stocker K, Hartmann M, Schmid Y, Vogt SB, Becker AM, Ley L, Straumann I, Arikci D, Klaiber A, Erne L, Vizeli P, Holze F, Liechti ME.
Europe PMC Published
psilocybin AnxietyConsciousnessHealthy Volunteers Clinical Trial
Classic psychedelics and related substances, such as 3,4-methylenedioxymethamphetamine (MDMA), have again become a focus of interest in psychiatry as potential therapeutic tools. The aim of this paper is to review current data on their mechanisms of action, clinical applications in the treatment of mood and anxiety disorders, addictions and post-traumatic st...
Unknown journal
2025-12-22
Liszka P, Ogórek A, Olejnik-Chlewicka KM, Puchalski K, Zasiadła M, Patrzykąt KM, Perediatkiewicz J, Urbański W, Łuczak PM, Brodowski J.
Europe PMC Published
psilocybin DepressionAnxietyPTSDAddictionMechanism of ActionReceptor PharmacologyEmotional ProcessingClinical TrialReview ArticleCancer PatientsTreatment-Resistant DepressionSafetyDrug Interactions Clinical Trial
Background and aimsThere is an urgent unmet need for novel treatments for methamphetamine (MA) use disorder. We explored the qualitative experiences of people participating in a study of psilocybin-assisted psychotherapy (PAT) to treat MA use disorder.Design and settingQualitative study of participants enrolled in a single arm, open-label pilot study of PAT ...
Unknown journal
2025-12-21
Brett J, Lea T, Knock E, Albert S, Acheson L, Siefried KJ, Job S.
Europe PMC Published
psilocybin Spirituality Qualitative Study
Unknown journal
2025-12-21
Palitsky R, Grant GH.
Europe PMC Published
psilocybin Spirituality Other
Unknown journal
2025-12-21
Authors unavailable
Europe PMC Published
psilocybin Spirituality Other
Unknown journal
2025-12-21
Brach T.
Europe PMC Published
psilocybin ConsciousnessSpirituality Other
Griffiths et al.'s recent "Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions" is an important study in the literature on psychedelic medicine and religious experience. In this commentary on the study, we argue: (1) The study design's implicit presupposition of perennialism in its conception ...
Unknown journal
2025-12-21
Lorenz J, Hawkins S, McCarthy B.
Europe PMC Published
psilocybin SpiritualityMystical ExperienceSafety Other
BackgroundAlthough historical writings, anthropological accounts, and experimental studies document associations between psilocybin use and religion, no prospective experimental study has investigated how the effects of psilocybin are experienced and interpreted by religious clergy. This exploratory study evaluated the overall safety and the acute and enduri...
Unknown journal
2025-12-21
Griffiths RR, Jesse R, Richards WA, Johnson MW, Sepeda ND, Bossis AP, Ross S.
Europe PMC Published
psilocybin WellbeingSpiritualitySafetyAdverse Events Clinical Trial